| HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now I Schlam, SM Swain NPJ breast cancer 7 (1), 56, 2021 | 154 | 2021 |
| Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler H Bergholtz, JM Carter, A Cesano, MCU Cheang, SE Church, P Divakar, ... Cancers 13 (17), 4456, 2021 | 61 | 2021 |
| Carfilzomib: a cause of drug associated thrombotic microangiopathy I Qaqish, IM Schlam, HA Chakkera, R Fonseca, J Adamski Transfusion and Apheresis Science 54 (3), 401-404, 2016 | 38 | 2016 |
| PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myeloma S Panchabhai, I Schlam, S Sebastian, R Fonseca Leukemia 31 (4), 991-994, 2017 | 31 | 2017 |
| Overcoming resistance to HER2-directed therapies in breast cancer I Schlam, P Tarantino, SM Tolaney Cancers 14 (16), 3996, 2022 | 29 | 2022 |
| The tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling I Schlam, SE Church, TD Hether, K Chaldekas, BM Hudson, AM White, ... Journal of translational medicine 19, 1-14, 2021 | 19 | 2021 |
| How I treat HER2-low advanced breast cancer I Schlam, SM Tolaney, P Tarantino The Breast 67, 116-123, 2023 | 14 | 2023 |
| Case report: primary osteonecrosis associated with thrombophilia-hypofibrinolysis and worsened by testosterone therapy MI Jarman, K Lee, A Kanevsky, S Min, I Schlam, C Mahida, A Huda, ... BMC hematology 17, 1-6, 2017 | 14 | 2017 |
| Efficacy, safety, low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal … P Shah, CJ Glueck, N Goldenberg, S Min, C Mahida, I Schlam, ... Lipids in Health and Disease 16, 1-12, 2017 | 11 | 2017 |
| Profile of Margetuximab: evidence to date in the targeted treatment of metastatic HER2-positive breast cancer I Schlam, R Nunes, F Lynce OncoTargets and therapy, 471-478, 2022 | 9 | 2022 |
| Filling the gap after CDK4/6 inhibitors: Novel endocrine and biologic treatment options for metastatic hormone receptor positive breast cancer A Mittal, C Molto Valiente, F Tamimi, I Schlam, S Sammons, SM Tolaney, ... Cancers 15 (7), 2015, 2023 | 8 | 2023 |
| Immune checkpoint inhibitors in the treatment of breast cancer brain metastases I Schlam, ME Gatti-Mays The Oncologist 27 (7), 538-547, 2022 | 8 | 2022 |
| Left ventricular assist devices in patients with active malignancies I Schlam, AY Lee, S Li, FH Sheikh, R Zaghlol, B Basyal, C Gallagher, ... Cardio Oncology 3 (2), 305-315, 2021 | 8 | 2021 |
| Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases? I Schlam, SM Tolaney Oncotarget 12 (9), 873, 2021 | 7 | 2021 |
| Safety and efficacy of CAR T cells in a patient with lymphoma and a coexisting autoimmune neuropathy KS Jhaveri, I Schlam, NG Holtzman, M Peravali, PK Richardson, S Dahiya, ... Blood Advances 4 (23), 6019-6022, 2020 | 6 | 2020 |
| Emerging targeted therapies for early breast cancer I Schlam, P Tarantino, S Morganti, F Lynce, D Trapani, EL Mayer, ... Drugs 82 (14), 1437-1451, 2022 | 5 | 2022 |
| Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple negative breast cancer (TNBC) treated with adjuvant immunotherapy and/or … F Lynce Age (mean (SD) 51, 11.54, 2022 | 5 | 2022 |
| HOLA COVID-19 study: evaluating the impact of caring for patients with COVID-19 on cancer care delivery in Latin America C Bernabe-Ramirez, AI Velazquez, C Olazagasti, C Decat Bergerot, ... JCO global oncology 8, e2100251, 2022 | 4 | 2022 |
| BRCA1/2 mutations and risk‐reducing bilateral salpingo‐oophorectomy among Latinas: The UPTAKE study F Lynce, I Schlam, X Geng, BN Peshkin, S Friedman, J Dutil, Z Nahleh, ... Journal of genetic counseling 30 (2), 383-393, 2021 | 4 | 2021 |
| HER2‑positive breast cancer and tyrosine kinase inhibitors: the time is now. NPJ Breast Cancer. 2021; 7: 56 I Schlam, SM Swain | 4 | |
